141 related articles for article (PubMed ID: 37545433)
21. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis.
Zhang B; Liu Y; Zhou S; Jiang H; Zhu K; Wang R
Int Immunopharmacol; 2020 Mar; 80():106214. PubMed ID: 31982822
[TBL] [Abstract][Full Text] [Related]
22. Circulating tumor cells counts are associated with CD8+ T cell levels in programmed death-ligand 1-negative non-small cell lung cancer patients after radiotherapy: A retrospective study.
Liu Q; Zhao C; Jiang P; Liu D
Medicine (Baltimore); 2021 Jul; 100(29):e26674. PubMed ID: 34398034
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis.
Huang LJ; Deng XF; Chang F; Wu XL; Wu Y; Diao QZ
Medicine (Baltimore); 2018 Oct; 97(43):e12858. PubMed ID: 30412078
[TBL] [Abstract][Full Text] [Related]
24. Expression and analysis of PD-L1 in peripheral blood circulating tumor cells of lung cancer.
Wang W; Zhang T
Future Oncol; 2021 May; 17(13):1625-1635. PubMed ID: 33726500
[No Abstract] [Full Text] [Related]
25. Comparison of different predictive biomarker testing assays for PD-1/PD-L1 checkpoint inhibitors response: a systematic review and network meta-analysis.
Shi H; Zhang W; Zhang L; Zheng Y; Dong T
Front Immunol; 2023; 14():1265202. PubMed ID: 37822932
[TBL] [Abstract][Full Text] [Related]
26. Efficacy relevance of PD-L1 expression on circulating tumor cells in metastatic breast cancer patients treated with anti-PD-1 immunotherapy.
Zhou Y; Zhou J; Hao X; Shi H; Li X; Wang A; Hu Z; Yang Y; Jiang Z; Wang T
Breast Cancer Res Treat; 2023 Jul; 200(2):281-291. PubMed ID: 37227611
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of blood-based PD-L1 analysis in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
Cui Q; Li W; Wang D; Wang S; Yu J
World J Surg Oncol; 2023 Oct; 21(1):318. PubMed ID: 37821941
[TBL] [Abstract][Full Text] [Related]
28. Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC.
Kloten V; Lampignano R; Krahn T; Schlange T
Cells; 2019 Aug; 8(8):. PubMed ID: 31374957
[TBL] [Abstract][Full Text] [Related]
29. The diagnostic value of circulating tumor cells for lung cancer: A systematic review and meta-analysis.
Ye Y; Li SL; Wang JJ; Liu B
Medicine (Baltimore); 2019 Mar; 98(12):e14936. PubMed ID: 30896658
[TBL] [Abstract][Full Text] [Related]
30. Dynamic monitoring of PD-L1 and Ki67 in circulating tumor cells of metastatic non-small cell lung cancer patients treated with pembrolizumab.
Spiliotaki M; Neophytou CM; Vogazianos P; Stylianou I; Gregoriou G; Constantinou AI; Deltas C; Charalambous H
Mol Oncol; 2023 May; 17(5):792-809. PubMed ID: 36177552
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis.
Li J; Wang P; Xu Y
PLoS One; 2017; 12(6):e0179536. PubMed ID: 28604812
[TBL] [Abstract][Full Text] [Related]
32. In vivo detection of circulating tumor cells predicts high-risk features in patients with bladder cancer.
Jin D; Qian L; Xia J; Zhang R; Yang G; Zhang L; Xue W; Cao M; Dong L; Chen H
Med Oncol; 2023 Mar; 40(4):113. PubMed ID: 36884136
[TBL] [Abstract][Full Text] [Related]
33. The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis.
Chen XJ; Yuan SQ; Duan JL; Chen YM; Chen S; Wang Y; Li YF
Dis Markers; 2020; 2020():6717912. PubMed ID: 33488843
[TBL] [Abstract][Full Text] [Related]
34. A meta-analysis reveals prognostic role of programmed death ligand-1 in Asian patients with non-small cell lung cancer.
Hu XY; Zhang W; Hu Y; Zhang Y; Gong R; Liang JY; Liu L
J Huazhong Univ Sci Technolog Med Sci; 2016 Jun; 36(3):313-320. PubMed ID: 27376797
[TBL] [Abstract][Full Text] [Related]
35. The potential diagnostic accuracy of circulating microRNAs for prostate cancer: A meta-analysis.
Zhang WT; Zhang GX; Zhao RZ; Gao SS
Actas Urol Esp (Engl Ed); 2022 Apr; 46(3):138-149. PubMed ID: 35260368
[TBL] [Abstract][Full Text] [Related]
36. Investigating Radiotherapy Effects on PD-L1 Expression in Circulating Tumor Cells: An Exploratory Study.
Rafli R; Harahap WA; Gondhowiardjo S; Ekaputra A
Asian Pac J Cancer Prev; 2024 May; 25(5):1559-1566. PubMed ID: 38809627
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis.
Xian F; Ren D; Bie J; Xu G
Front Immunol; 2023; 14():1119168. PubMed ID: 37138876
[TBL] [Abstract][Full Text] [Related]
38. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.
Qian X; Chen H; Tao Y
Front Immunol; 2023; 14():1146898. PubMed ID: 37063822
[TBL] [Abstract][Full Text] [Related]
39. The Association Between Imaging Features of TSCT and the Expression of PD-L1 in Patients With Surgical Resection of Lung Adenocarcinoma.
Wu T; Zhou F; Soodeen-Lalloo AK; Yang X; Shen Y; Ding X; Shi J; Dai J; Shi J
Clin Lung Cancer; 2019 Mar; 20(2):e195-e207. PubMed ID: 30514666
[TBL] [Abstract][Full Text] [Related]
40. Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer.
Jacot W; Mazel M; Mollevi C; Pouderoux S; D'Hondt V; Cayrefourcq L; Bourgier C; Boissiere-Michot F; Berrabah F; Lopez-Crapez E; Bidard FC; Viala M; Maudelonde T; Guiu S; Alix-Panabières C
Clin Chem; 2020 Aug; 66(8):1093-1101. PubMed ID: 32712650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
